Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Zaltoprofen inhibits concanavalin A-induced decrease of body weight in mice.

T Okamoto1, T Kawasaki, Y Masuda

  • 1Research Laboratories, Nippon Chemiphar Co., Ltd., Saitama 341-0005, Japan.

International Journal of Molecular Medicine
|August 9, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Resin glycosides. XV. Simonins I-V, ether-soluble resin glycosides (jalapins) from the roots of Ipomoea batatas (cv. Simon).

Chemical & pharmaceutical bulletin·1992
Same author

Characterization of a glucuronyltransferase: neolactotetraosylceramide glucuronyltransferase from rat brain.

Glycoconjugate journal·1992
Same author

Short-term modulation of cerebellar Purkinje cell activity after spontaneous climbing fiber input.

Journal of neurophysiology·1992
Same author

Identification, purification and reconstitution of thiamin metabolizing enzymes in human red blood cells.

Biochimica et biophysica acta·1992
Same author

Immunological identification of a Cl- channel protein in electric organs of Narke japonica.

Biochemical and biophysical research communications·1992
Same author

Multivalent ligand binding by serum mannose-binding protein.

Archives of biochemistry and biophysics·1992
Same journal

Exercise and fluoxetine in Alzheimer's disease: Molecular mechanisms of synergistic and antagonistic effects (Review).

International journal of molecular medicine·2026
Same journal

[Corrigendum] Arginine ADP‑ribosyltransferase 1 promotes angiogenesis in colorectal cancer via the PI3K/Akt pathway.

International journal of molecular medicine·2026
Same journal

Oral‑gut axis in systemic disease: A barrier‑metabolism‑immunity three‑dimensional regulatory model (Review).

International journal of molecular medicine·2026
Same journal

Endothelial dysfunction: A central mechanism linking autosomal dominant polycystic kidney disease and intracranial aneurysms (Review).

International journal of molecular medicine·2026
Same journal

ABCG2 transporter: Structural and functional associations with gout (Review).

International journal of molecular medicine·2026
Same journal

Research progress on the chemical and pharmacological effects of <i>Semen Strychni</i> (Review).

International journal of molecular medicine·2026
See all related articles

Zaltoprofen, a non-steroidal anti-inflammatory drug, effectively inhibited weight loss and reduced food intake in mice treated with concanavalin A (Con A). This suggests Zaltoprofen may treat sickness behavior.

Area of Science:

  • Pharmacology
  • Immunology
  • Neuroscience

Background:

  • Concanavalin A (Con A) is a T-cell mitogen that induces an inflammatory response in mice, characterized by decreased body weight, food intake, and water intake.
  • This Con A-induced response is often used as a model for studying sickness behavior, a complex set of behavioral and physiological changes that occur during illness.

Purpose of the Study:

  • To investigate the effect of Zaltoprofen, a non-steroidal anti-inflammatory drug (NSAID), on Con A-induced sickness behavior in mice.
  • To determine if Zaltoprofen can mitigate the reduction in body weight and food intake caused by Con A.

Main Methods:

  • Mice were treated with Con A (12.5 mg/kg, i.v.) to induce sickness behavior.
  • Zaltoprofen (10 mg/kg) was administered 8 hours after Con A treatment.

Related Experiment Videos

  • Body weight, food intake, and water intake were measured at 24 hours post-Con A treatment.

    • Main Results:

    • Con A treatment significantly decreased body weight, food intake, and water intake in mice.
    • Zaltoprofen administration significantly inhibited the Con A-induced reduction in body weight.
    • Food intake in mice treated with Con A plus Zaltoprofen was four times greater than in mice treated with Con A alone.

    Conclusions:

    • Zaltoprofen effectively inhibits Con A-induced sickness behavior in mice, specifically mitigating body weight loss and reduced food intake.
    • These findings suggest that Zaltoprofen may be a potential therapeutic agent for managing sickness behavior associated with inflammatory conditions.